Restaging with gallium scan identifies chemosensitive patients and predicts survival of poor-prognosis mediastinal Hodgkin's disease patients

Medical Oncology

Volumn 17, Issue 2, 2000, Pages 127-134

  Ionescu, I ^a   Brice, P ^a   Simon, D ^a   Guermazi, A ^a   Leblanc, T ^a   Rousselot, P ^a   Gossot, D ^a   Meignin, V ^a   Gisselbrecht, C ^a   Rain, J D ^a  

^a SAINT LOUIS HOSPITAL   (France)

Author keywords

Chemotherapy; Gallium; Hodgkin's disease; Mediastinal disease; Predictive value

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CHLORMETHINE; DACARBAZINE; DOXORUBICIN; GALLIUM 67; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; VINDESINE;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCINTISCANNING; CANCER STAGING; CANCER SURVIVAL; FEMALE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM MASS; PRIORITY JOURNAL; PROGNOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0034042655     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02796208     Document Type: Article

References (29)

1. 1 Carde P et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. J Clin Oncol 1988; 6: 239-252.
2. 2 Strauss DJ et al. Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross resistant chemotherapy and intermediate-dose radiotherapy. J Clin Oncol 1990; 8: 1173-1186.
3. 3 Israel O et al. Gallium-67 imaging in monitoring lymphoma response to treatment. Cancer 1988; 61: 2439-2443.
4. 4 Kostakoglu L et al. Validation of gallium-67-citrate single photon emission computed tomography in biopsy-confirmed residual Hodgkin's disease in the mediastinum. J Nucl Med 1992; 33: 345-350.
5. 5 McLaughlin AF, Southee AE. Gallium scintigraphy in tumor diagnosis and management. In: IPC Murray, PJ EII (eds.). Nuclear Medicine in Clinical Diagnosis and Treatment, vol. 2. Churchill Livingstone: Edinburgh, 1994, pp 711-725.
6. 6 Wylie BR et al. Gallium scanning in the management of mediastinal Hodgkin's disease. Eur J Haematol 1989; 42: 344-347.
7. 7 Southee AE et al. Gallium scanning as a predictor of outcome in mediastinal Hodgkin's disease. Eur J Nucl Med 1989; 15: 547-551.
8. 8 Kaplan WD et al. Gallium-67 imaging: a predictor of residual tumor viability and clinical outcome in patients with diffuse large-cell lymphoma. J Clin Oncol 1990; 8: 1966-1970.
9. 9 Front D, Israel O. The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. Semin Nucl Med 1995; 25: 60-71.
10. 10 King SC, Reiman RJ, Prosnitz LR. Prognostic importance of restaging gallium scans following induction chemotherapy for advanced Hodgkin's disease. J Clin Oncol 1994; 12: 306-3111.
11. 11 Hagemeister FB et al. The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy. Ann Oncol 1994; 5(Suppl 2): 59-63.
12. 12 Janicek M et al. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-Hodgkin's lymphoma treated with high-dose CHOP chemotherapy. J Clin Oncol 1997; 15: 1631-1637.
13. 13 Tumeh SS et al. Lymphoma: evaluation with Ga-67 SPECT. Radiology 1987; 164: 111-114.
14. 14 Brice P et al. Residual mediastinal mass in malignant lymphoma: value of magnetic resonance imaging and gallium scan. Nouv Rev Fr Hematol 1993; 35: 457-461.
15. 15 Hubner KF, Buonocore E, Singh SK, Gould HR, Gotten DW. Characteriation of chest masses by FDG positron emission tomography. Clin Nucl Med 1995; 20: 293-298.
16. 16 Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-1514.
17. 17 Cheson BD et al. Report of an international workshop to standardize response criteria for non Hodgkin's lymphomus. J Clin Oncol 1999; 17: 1244-1253.
18. 18 Kaplan ES, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-461.
19. 19 Andre M et al. Results of 3 courses of ABVD with subtotal nodal irradiation in 189 patients with nodal Hodgkin's disease (stage I, II, IIIA). Hematol Cell Ther 1997; 39: 59-65.
20. 20 Ferme C et al. Prognosis of patients with advanced Hodgkin's disease: evaluation of four prognostic models using 344 patients included in the GELA study. Cancer 1997; 80: 1124-1133.
21. 21 Harris EW, Rakow JI, Weiner M, Agress H Jr. Thallium-201 scintigraphy for assessement of a gallium-67-avid mediastinal mass following therapy for Hodgkins disease. J Nucl Med 1993; 34: 1326-1330.
22. 22 Gasparini MD et al. Current role of Gallium scan and magnetic resonance imaging in the management of mediastinal Hodgkin lymphoma. Cancer 1993; 72: 577-582.
23. 23 Salloum E et al. Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients. J Clin Oncol 1997; 15: 518-527.
24. 24 Bartold SP et al. Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. J Nucl Med 1997; 38: 990-994.
25. 25 Bogart JA et al. The value of gallium imaging after therapy for Hodgkin's disease. Cancer 1998; 82: 754-759.
26. 26 Jerusalem G et al. Whole body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. Nucl Med Commun 1999; 20: 13-20.
27. 27 Cremerius U et al. Clinical value of FDG PET for therapy monitoring of malignant lymphoma-results of a retrospective study in 72 patients. Nuklearmedizin 1999; 38: 24-30.
28. 28 Devizzi L et al. Comparison of gallium scan, computed tomography and magnetic resonance in patients with mediastinal Hodgkin's disease. Ann Oncol 1997; 8 (Suppl 1): 53-57.
29. 29 Jerusalem G et al. Whole-body positron emission tomography using FDG-PET for posttreatment evaluation of Hodgkins disease and non-Hodgkins lymphoma has higher diagnosistic and prognostic value than classical CT scan imaging. Blood 1999; 94: 429-433.